Résumé
The microbiome consists of all microbes present on and within the human body. An unbalanced, or 'dysbiotic' intestinal microbiome is associated with inflammatory bowel disease, diabetes and some cancer types. Drug treatment can alter the intestinal microbiome composition. Additionally, some chemotherapeutics interact with microbiome components, leading to changes in drug safety and/or efficacy. The intestinal microbiome is a modifiable target, using strategies such as antibiotic treatment, fecal microbial transplantation or probiotic administration. Understanding the impact of the microbiome on the safety and efficacy of cancer treatment may result in improved treatment outcome. The present review seeks to summarize relevant research and look to the future of cancer treatment, where the intestinal microbiome is recognized as an actionable treatment target.
| Langue d'origine | English |
|---|---|
| Pages (de-à) | 4371-4387 |
| Nombre de pages | 17 |
| Journal | Future Oncology |
| Volume | 17 |
| Numéro de publication | 32 |
| DOI | |
| Statut de publication | Published - nov. 2021 |
Note bibliographique
Funding Information:J Wertman reports funding from an IWK Health Centre Postdoctoral Fellowship. K Dunn reports funding from an IWK Research Associateship. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Publisher Copyright:
© 2021 Future Medicine Ltd.
ASJC Scopus Subject Areas
- Oncology
- Cancer Research
PubMed: MeSH publication types
- Journal Article
- Review
ODD de l’ONU
Cette action contribue à la réalisation des objectifs de développement durable suivants
